Abstract

Aim of the study

Myofascial pain syndrome (MPS) is a common problem in the general population. MPS should not be a local/peripheral painful syndrome and considered to be a syndrome of central sensitivity. We aimed to investigate the effect of pregabalin in patients with MPS in this study.

Materials and methods

We randomized 40 patients into two groups, and 17 patients per group completed the study. Female patients in group I received pregabalin and exercise therapy, whereas those in group II received exercise therapy alone. All patients were evaluated as follows: for pain by visual analog scale (VAS); trigger-point pressure pain threshold-(PPT) by algometry; neuropathic pain using the Douleur Neuropathique en 4 Questions (DN4) and quality of life with the Short Form-36 (SF36). Evaluations were performed pre-treatment and at the end of the first and third months of treatment. Clinical trial ID: NCT04600037, retrospectively registered 20/10/2020.

Results

In group I, significant improvements were observed in VAS, trigger-point-PPT, physical component summary-SF-36, at the first and third months. In group II, statistically significant improvements were observed in VAS, trigger-point-PPT after the first and third months. Group I showed statistically better improvements in VAS, trigger points-PPT, physical component summary-SF36 compared with group II by the third month.

Conclusion

Pregabalin treatment is effective for controlling trigger points. Pregabalin treatment is also more effective than exercise treatment at improving quality of life in patients with MPS.

中文翻译：

---

普瑞巴林治疗肌筋膜疼痛综合征和纤维肌痛综合征患者触发点的有效性：一项随机对照试验

摘要

研究目的

肌筋膜疼痛综合征 (MPS) 是普通人群中的常见问题。MPS 不应是局部/外周疼痛综合征，应被视为中枢敏感性综合征。本研究旨在探讨普瑞巴林对 MPS 患者的影响。

材料和方法

我们将 40 名患者随机分为两组，每组 17 名患者完成了研究。I组女性患者接受普瑞巴林和运动疗法，而II组女性患者仅接受运动疗法。所有患者的评估如下：通过视觉模拟量表（VAS）评估疼痛；触发点压力痛阈 - (PPT) 测痛法; 使用 Douleur Neuropathique en 4 Questions (DN4) 的神经性疼痛和使用 Short Form-36 (SF36) 的生活质量。在治疗前和治疗的第一个月和第三个月结束时进行评估。临床试验编号：NCT04600037，2020年10月20日追溯注册。

结果

在第一组和第三个月，观察到 VAS、触发点-PPT、物理成分总结-SF-36 的显着改善。在第 II 组中，在第一个月和第三个月后观察到 VAS、触发点-PPT 的统计学显着改善。到第三个月，与第二组相比，第一组在 VAS、触发点 - PPT、身体成分总结 - SF36 方面表现出统计学上更好的改善。

结论

普瑞巴林治疗可有效控制触发点。在改善 MPS 患者的生活质量方面，普瑞巴林治疗也比运动治疗更有效。